Mercaptor Discoveries CEO to Speak at Horasis Global Meeting in Cascais, Portugal April 7, 2019 and Private Investment Forum Worldwide in Zurich April 9
NOVATO, Calif., April 5, 2019 /PRNewswire/ -- Mercaptor Discoveries (Mercaptor), a company developing Captons™, small molecules that have reproducible preclinical Proof of Concept (POC) for generating neuroprotectants exclusively at the site of injury, announced today that Sara Isbell, CEO, President and Co-Founder of Mercaptor Discoveries, will be a speaker and panel chairperson at the Horasis Global Meeting in Cascais, Portugal April 7, 2019. Isbell will also speak at the VII Private Investment Forum Worldwide, taking place in Zurich, Switzerland on April 9, 2019.
Founded by Dr. Frank-Jürgen Richter, former Director of the World Economic Forum, the annual Horasis Global Meeting is one of the foremost invitation-only gatherings of business and government leaders, offering an ideal platform to foster and explore cooperation, impact investing, and sustainable growth across the world. This year the conference will host more than 700 participants and discussions will center around the theme of "Catalyzing the Benefits of Globalization."
Mercaptor CEO Sara Isbell will chair the Conquering Global Illness panel, which brings together leaders and experts from healthcare, nutrition, pharmaceuticals and bio-capital to explore the potential to provide global universal healthcare and its beneficial impact on economic growth.
Following the Horasis Global Meeting, Isbell will speak in Zurich on April 9 at the VII Private Investment Forum Worldwide, a gathering of top business leaders, Family Offices and entrepreneurs from GCC, UK, US and Europe. In partnership with Strategic Swiss Partners (SSP), Isbell will introduce Mercaptor and its plans to develop Capton-based, locally generated medicine to delegates.
Mercaptor has partnered with SSP on a long-term working relationship and has collaborated with SSP's Medical Core Team, Karin Van Zuilen and Coert Huijbregsen, to develop strategy and communications.
"All the partners at SSP are selective about what projects we take on. We look for unique things to engage in and Mercaptor fit that criteria," said Guna R. Mahalingam, Founder and CEO of SSP. "We are excited about Mercaptor's discovery and are passionate about the potential of Captons to treat Alzheimer's and other brain conditions. We are committed to going the distance with Mercaptor," he continued.
About Mercaptor Discoveries
Mercaptor Discoveries was founded by a scientific team with experience developing successful biotech companies, including Raptor Pharmaceuticals. Raptor was purchased by Horizon Pharma in 2016 for $860M USD. Mercaptor's founding scientists discovered injury-activated molecules, called Captons™. Captons have reproducible preclinical POC as neuroprotectants and have potential to prevent the progression of Central Nervous System disorders and neurodegenerative diseases such as Alzheimer's disease, ALS, CTE, Parkinson's disease, MS and stroke. Each member of Mercaptor's team prioritizes productivity and transparency and values the purity of research. To learn more, visit www.mercaptor.com.
About SSP
Strategic Swiss Partners is a globally connected leading boutique management and financial advisory firm with multiple years of industry experience of initiating and enhancing business opportunities and investments across a wide variety of sectors. www.strategicswisspartners.com
Contact: Carole Barrow, [email protected], 415-870-6997
SOURCE Mercaptor Discoveries
Share this article